Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.35 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.34 |
| ▸ | GBA1 | P04062 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.31 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.31 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.31 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.31 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.31 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.31 |
| ▸ | PYGL | P06737 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12083286 | 1.00 | GBA2 (0.35) | GBA2LGALS3GBA1ALDH1A1TSHR | |
| SCHEMBL5594313 | 1.00 | GBA2 (0.35) | GBA2LGALS3GBA1ALDH1A1TSHR | |
| SCHEMBL7772026 | 1.00 | GBA2 (0.35) | GBA2LGALS3GBA1ALDH1A1TSHR | |
| SCHEMBL15145344 | 1.00 | GBA2 (0.35) | GBA2LGALS3GBA1ALDH1A1TSHR | |
| SCHEMBL13969566 | 1.00 | GBA2 (0.35) | GBA2LGALS3GBA1ALDH1A1TSHR | |
| SCHEMBL24246852 | 1.00 | GBA2 (0.35) | GBA2LGALS3GBA1ALDH1A1TSHR | |
| SCHEMBL7772022 | 1.00 | GBA2 (0.35) | GBA2LGALS3GBA1ALDH1A1TSHR | |
| SCHEMBL22640981 | 1.00 | GBA2 (0.35) | GBA2LGALS3GBA1ALDH1A1TSHR | |
| SCHEMBL21479622 | 1.00 | GBA2 (0.35) | GBA2LGALS3GBA1ALDH1A1TSHR | |
| SCHEMBL14339490 | 1.00 | GBA2 (0.35) | GBA2LGALS3GBA1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103554194-B | The manufacture method of sugar oxazoline derivative | SEIKAGAKU KOGYO CO., LTD. (JP) | 2016-03-09 | — | — | CN | claimed |
| US-20040033967-A1 | Alkylated hexitol nucleoside analogues and oligomers thereof | K.U.LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2004-02-19 | — | — | US | claimed |
| EP-0739333-B1 | SELECTIVE ASYMMETRIC HYDROGENATION OF DEHYDROAMINO ACID DERIVATIVES USING RHODIUM AND IRIDIUM DIPHOSPHINITE CARBOHYDRATE CATALYST COMPOSITIONS | DU PONT (US) | 1998-10-14 | — | — | EP | claimed |
| WO-1997018222-A2 | NOVEL OLIGOSACCHARIDE GLYCOSIDES HAVING MAMMALIAN IMMUNOSUPPRESSIVE AND TOLEROGENIC PROPERTIES | GLYCOMED, INC. (US) | 1997-05-22 | — | — | WO | claimed |
| EP-4326314-A2 | AN FC GLYCAN REMODELING FOR SITE-SPECIFIC ANTIBODY CONJUGATION AND APPLICATIONS THEREOF | University of Maryland, College Park (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230276834-A1 | COMPOSITION COMPRISING GLUCOSYLATED STEVIA AND HAVING IMPROVED SWEETNESS QUALITY | CJ CHEILJEDANG CORPORATION (KR) | 2023-09-07 | — | — | US | disclosed |
| WO-2023150695-A1 | ALTERING NET CHARGE ON MANNOSYLATED DEXTRANS TO MAXIMIZE TARGET TISSUE UPTAKE AND OFF TARGET COMPETITIVE BLOCKING | NAVIDEA BIOPHARMACEUTICALS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| EP-3119761-B1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | AMYDIS DIAGNOSTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11649222-B2 | Compounds | UNIVERSITETET I OSLO (NO) | 2023-05-16 | — | — | US | disclosed |
| WO-2023011597-A1 | LIGAND CONJUGATES FOR DELIVERY OF THERAPEUTICALLY ACTIVE AGENTS | Hepagene Therapeutics (HK) Limited (CN) | 2023-02-09 | — | — | WO | disclosed |
| US-11547681-B2 | N-acylethanolamide derivatives and uses thereof | ELIEM THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2022226420-A2 | AN FC GLYCAN REMODELING PLATFORM METHOD FOR SITE-SPECIFIC ANTIBODY CONJUGATION AND APPLICATIONS THEREOF | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2022-10-27 | — | — | WO | disclosed |
| EP-0720616-A1 | NOVEL DEOXY AND OXYGEN-SUBSTITUTED SUGAR-CONTAINING 14-AMINOSTEROID COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995021172-A1 | PROCESS FOR EPOXIDISING PROCHIRAL OLEFINS AND A CATALYST THEREFOR AND INTERMEDIATES FOR MAKING THE CATALYST | SMITHKLINE BEECHAM P.L.C. (GB) | 1995-08-10 | — | — | WO | disclosed |
| EP-0655950-A1 | CHIRAL CATALYSTS AND EPOXIDATION REACTIONS CATALYZED THEREBY. | SMITHKLINE BEECHAM PLC (GB) | 1995-06-07 | — | — | EP | disclosed |
| WO-1995008557-A1 | NOVEL OLIGOSACCHARIDE-CONTAINING 14-AMINOSTEROID COMPOUNDS AND NOVEL DIASTEREOSELECTIVE AMINOSTEROID PROCESS CHEMISTRY | THE PROCTER & GAMBLE COMPANY (US) | 1995-03-30 | — | — | WO | disclosed |
| WO-1995008558-A1 | NOVEL DEOXY AND OXYGEN-SUBSTITUTED SUGAR-CONTAINING 14-AMINOSTEROID COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1995-03-30 | — | — | WO | disclosed |
| WO-1994003271-A1 | CHIRAL CATALYSTS AND EPOXIDATION REACTIONS CATALYZED THEREBY | SMITHKLINE BEECHAM PLC (GB) | 1994-02-17 | — | — | WO | disclosed |
| WO-1992003122-A1 | PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS | CEVC GREGOR (DE) | 1992-03-05 | — | — | WO | disclosed |
| EP-0089812-A1 | N-substituted pseudo-aminosugars, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1983-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033967-A1 | Alkylated hexitol nucleoside analogues and oligomers thereof | DERA, HEXA, HEXB | GBA2 735/4885LGALS3 558/4885GBA1 475/4885 |
| US-11649222-B2 | Compounds | SLC30A6, SLC39A11, SLC39A3 | GBA2 336/4885LGALS3 2852/4885GBA1 468/4885 |
| US-11547681-B2 | N-acylethanolamide derivatives and uses thereof | FAAH, FAAH2, NAAA | GBA2 100/4885LGALS3 2543/4885GBA1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.